Literature DB >> 18050846

Management of anorectal melanomas: a 10-year review.

Arun W S David1, B Perakath.   

Abstract

BACKGROUND: Anorectal melanoma (AM) is a rare tumour with poor prognosis. The primary modality of treatment for AM is surgery. However, the choice of operation is controversial. Historically, radical operations like abdominoperineal excision of rectum (APER) with or without inguinal lymph node dissection were preferred. However, as no stage-specific survival advantage has been seen with APER later studies have recommended wide local excision (WLE) as the preferred treatment where negative margins can be achieved. The aim of our study was to review our results.
METHODS: Inpatient and outpatient charts of all patients treated for AM between 1996 and 2005 were reviewed. Patient characteristics, clinical presentation, evaluation, staging, treatment, complications and followup were studied. Patients were followed up to assess disease free and overall survival according to the stage of disease and the surgical procedure performed.
RESULTS: 17 patients were treated for AM between 1996 and 2005. At presentation 4 (23%) had metastatic and 1 (6%) had inoperable disease. 12 patients (71%) had operative therapy of which 10 had APER and two had WLE. 82% of these patients were followed up for a mean duration of 8 months (range 3-30 months) and their overall and disease free survival compared. The stage specific disease free and overall survival for patients who underwent APER was 8 months and 13 months for stage I and 7 months and 10 months for stage II respectively. The disease free survival and overall survival for patients who underwent WLE, both for stage I disease, was 10 months and 27 months respectively.
CONCLUSION: Despite surgical resection and emergence of various forms of adjuvant therapy, the overall prognosis of anorectal melanoma remains dismal. From a review of literature and our own experience, though limited, we conclude that WLE be recommended where negative margins can be achieved and where this is technically feasible. APER should be reserved for large tumours where WLE is not technically possible.

Entities:  

Mesh:

Year:  2007        PMID: 18050846

Source DB:  PubMed          Journal:  Trop Gastroenterol        ISSN: 0250-636X


  5 in total

1.  Melanoma of the anal canal.

Authors:  Rogerio Serafim Parra; Ana Luiza Normanha Ribeiro de Almeida; Giovana Bachega Badiale; Margarida Maria Fernandes da Silva Moraes; José Joaquim Ribeiro Rocha; Omar Féres
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

2.  A first reported case of metastatic anorectal amelanotic melanoma with a marked response to anti-PD-1 antibody nivolumab: A case report.

Authors:  Katsuji Tokuhara; Kazuyoshi Nakatani; Hirotsugu Tanimura; Kazuhiko Yoshioka; Takahiro Kiyohara; Masanori Kon
Journal:  Int J Surg Case Rep       Date:  2017-01-23

3.  Malignant melanoma of the anal canal: a case report.

Authors:  Roxana Barbus; Alin Rancea; Bogdan Fetica; Zeno Spârchez; Gabriel Kacsó
Journal:  J Contemp Brachytherapy       Date:  2009-10-08

4.  Genetic alteration of Chinese patients with rectal mucosal melanoma.

Authors:  Huan Li; Lujing Yang; Yumei Lai; Xintong Wang; Xinyin Han; Siyao Liu; Dongliang Wang; Xiaojuan Li; Nana Hu; Yan Kong; Lu Si; Zhongwu Li
Journal:  BMC Cancer       Date:  2021-05-27       Impact factor: 4.430

5.  Surgical treatment of anorectal melanoma: a systematic review and meta-analysis.

Authors:  Esther Jutten; Schelto Kruijff; Anne Brecht Francken; Martijn F Lutke Holzik; Barbara L van Leeuwen; Henderik L van Westreenen; Kevin P Wevers
Journal:  BJS Open       Date:  2021-11-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.